Abstract
With the emergence and re-emergence of infectious diseases and development of multi-drug resistance, there is a dire need to find newer cures and to produce more drugs and vaccines in the pipeline. To meet these increasing demands biomedical researchers and pharmaceutical companies are combining advanced methods of drug discovery, such as combinatorial chemistry, high-throughput screening and genomics, with conventional approaches using natural products and traditional knowledge. However, such approaches require much international cooperation and understanding of international laws and conventions as well as local customs and traditions. This article reviews the forty years of cumulative experience at the National Institutes of Health (initiated by the National Cancer Institute) in natural products drug discovery. It presents (1) three major cooperative programs (2) the legal mechanisms for cooperation and (3) illustrative case studies from these programs. We hope that these discussions and our lessons learned would be helpful to others seeking to develop their own models of cooperation for the benefit of global health.
Keywords: Plant-derived compounds, ADME, Developmental therapeutics program (DTP), Drug discovery, anti-HIV drugs
Current Drug Discovery Technologies
Title: Natures Medicines: Traditional Knowledge and Intellectual Property Management. Case Studies from the National Institutes of Health (NIH), USA
Volume: 2 Issue: 4
Author(s): Ranjan Gupta, Bjarne Gabrielsen and Steven M. Ferguson
Affiliation:
Keywords: Plant-derived compounds, ADME, Developmental therapeutics program (DTP), Drug discovery, anti-HIV drugs
Abstract: With the emergence and re-emergence of infectious diseases and development of multi-drug resistance, there is a dire need to find newer cures and to produce more drugs and vaccines in the pipeline. To meet these increasing demands biomedical researchers and pharmaceutical companies are combining advanced methods of drug discovery, such as combinatorial chemistry, high-throughput screening and genomics, with conventional approaches using natural products and traditional knowledge. However, such approaches require much international cooperation and understanding of international laws and conventions as well as local customs and traditions. This article reviews the forty years of cumulative experience at the National Institutes of Health (initiated by the National Cancer Institute) in natural products drug discovery. It presents (1) three major cooperative programs (2) the legal mechanisms for cooperation and (3) illustrative case studies from these programs. We hope that these discussions and our lessons learned would be helpful to others seeking to develop their own models of cooperation for the benefit of global health.
Export Options
About this article
Cite this article as:
Gupta Ranjan, Gabrielsen Bjarne and Ferguson M. Steven, Natures Medicines: Traditional Knowledge and Intellectual Property Management. Case Studies from the National Institutes of Health (NIH), USA, Current Drug Discovery Technologies 2005; 2 (4) . https://dx.doi.org/10.2174/157016305775202937
DOI https://dx.doi.org/10.2174/157016305775202937 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Current Cardiology Reviews Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design Cytostatic Effect of the Nucleoside Analogue 2-Chloroadenosine on Human Prostate Cancer Cell Line
Current Pharmaceutical Analysis Mechanisms of Fetal and Neonatal Renal Impairment by Pharmacologic Inhibition of Angiotensin
Current Medicinal Chemistry Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Current Neuropharmacology Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Subject Index To Volume 13
Current Medicinal Chemistry Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery Severe Hyponatremia and Other Electrolyte Disturbances Associated with Indapamide
Current Drug Safety Turner Syndrome : How Is It Made Up?
Current Genomics SARS-CoV-2 & Covid-19: Key-Roles of the ‘Renin-Angiotensin’ System / Vitamin D Impacting Drug and Vaccine Developments
Infectious Disorders - Drug Targets The Impact of IKr Blockade on Medicinal Chemistry Programs
Current Topics in Medicinal Chemistry Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Pathogenesis and Treatment of Secondary Hyperparathyroidism in Dialysis Patients: The Role of Paricalcitol
Current Vascular Pharmacology Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy